Description
CT-322 is an investigational drug being studied as a potential treatment for metastatic colorectal cancer (CRC). It is being evaluated in clinical trials, specifically in a Phase 2 study (NCT00851045), to see if it can be an effective option for patients whose cancer has progressed after initial treatment. In this trial, CT-322 is being tested in combination with standard chemotherapy drugs (irinotecan, 5-FU, and leucovorin) and compared to another anti-angiogenic drug, bevacizumab, also given with the same chemotherapy regimen. The goal is to see if CT-322 offers similar or better benefits in the second-line setting for patients with advanced CRC.
Mechanism of Action
CT-322 is described as a novel anti-angiogenic agent. Angiogenesis is the process where tumors create new blood vessels to help them grow and spread. Anti-angiogenic agents work by interfering with this process, aiming to cut off the tumor's blood supply and potentially slow its growth or spread. The specific way CT-322 interferes with angiogenesis is being studied in clinical trials.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.